- GLP-1 Medications: Benefits Beyond Weight Loss/
- GLP-1s & Health Conditions/
- GLP-1 Medications and Stroke Prevention: What SELECT and SUSTAIN 6 Show/
GLP-1 Medications and Stroke Prevention: What SELECT and SUSTAIN 6 Show
The SELECT trial showed semaglutide reduced major cardiovascular events — including stroke — by 20% in people with obe...
TL;DR: Semaglutide has FDA approval for reducing the risk of cardiovascular death, heart attack, and stroke — the first weight-loss drug ever approved for this purpose. The SELECT trial (17,604 participants) showed a 20% reduction in major cardiovascular events, and the earlier SUSTAIN 6 trial found a 39% reduction in nonfatal stroke specifically. The benefits start early — before maximum weight loss — suggesting direct vascular protection beyond weight reduction. GLP-1s work on top of standard care (statins, blood pressure meds, blood thinners). Telehealth access starts at $129/month.
The problem
Stroke and Obesity: The Connection #
Stroke is the fifth leading cause of death in the United States and a leading cause of serious long-term disability. About 795,000 Americans have a stroke every year, and roughly 87% are ischemic strokes — caused by blood clots blocking arteries to the brain.
Obesity dramatically increases stroke risk through multiple pathways:
- Hypertension — excess weight raises blood pressure, the single strongest stroke risk factor
- Atherosclerosis — obesity accelerates plaque buildup in carotid and cerebral arteries
- Atrial fibrillation — obesity increases AF risk, which is responsible for ~15% of all strokes
- Insulin resistance and inflammation — chronic metabolic inflammation damages blood vessel walls and promotes clot formation
- Sleep apnea — obesity-related sleep apnea causes nighttime oxygen drops that stress the cardiovascular system
Losing even 5-10% of body weight meaningfully reduces these risk factors. GLP-1 medications typically produce 15-20% weight loss — and appear to reduce stroke risk through additional mechanisms beyond weight alone.
Mechanisms
How GLP-1 Medications Protect Against Stroke #
GLP-1s attack stroke risk from multiple angles:
- Blood pressure reduction — semaglutide lowers systolic BP by 3-6 mmHg; tirzepatide by 7-8 mmHg
- Anti-inflammatory effects — C-reactive protein drops ~40%, reducing the arterial inflammation that destabilizes plaques
- Lipid improvement — triglycerides fall 15-20%, with modest LDL and HDL improvements
- Endothelial function — GLP-1 receptors on blood vessel walls improve vascular health directly
- Anti-atherosclerotic effects — preclinical data suggests GLP-1s may reduce plaque volume and stabilize vulnerable plaques
- Weight loss — reduces cardiac workload, blood pressure, and metabolic strain
A prespecified SELECT analysis published in The Lancet found only about one-third of semaglutide’s cardiovascular benefit was explained by changes in body measurements. The remaining two-thirds came from direct vascular and anti-inflammatory mechanisms — which is why the benefit appeared before maximum weight loss was achieved.
The evidence
What the Clinical Trials Show #
SELECT Trial (2023) — the landmark #
The SELECT trial enrolled 17,604 adults with established cardiovascular disease and obesity or overweight — but no diabetes — and randomized them to semaglutide 2.4 mg weekly or placebo for a mean of 40 months.
Key results:
- Major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, nonfatal stroke): 20% reduction (HR 0.80, p<0.001)
- Cardiovascular death: 15% reduction
- All-cause death: 19% reduction
- Event curves began separating within the first months of treatment
This trial led to the March 2024 FDA approval of Wegovy for cardiovascular risk reduction.
SUSTAIN 6 (2016) — the earlier diabetes trial #
The SUSTAIN 6 trial tested semaglutide in people with type 2 diabetes and high cardiovascular risk. It found a 39% reduction in nonfatal stroke — the strongest stroke-specific signal in GLP-1 trial data.
A post hoc analysis of stroke subtypes across SUSTAIN 6 and PIONEER 6 found the stroke reduction was driven primarily by fewer ischemic strokes (the most common type), consistent with GLP-1s’ anti-atherosclerotic and anti-inflammatory mechanisms.
Who benefits
Who Should Consider GLP-1 Therapy for Stroke Risk #
Strongest case for GLP-1 therapy:
- Prior stroke or TIA (transient ischemic attack)
- Established cardiovascular disease + BMI 27+
- Carotid artery stenosis with obesity
- Multiple risk factors: hypertension + high cholesterol + obesity
- Atrial fibrillation with obesity (weight loss reduces AF burden)
- Sleep apnea (tirzepatide is FDA-approved for moderate-to-severe OSA)
Important: GLP-1 medications complement, not replace, standard stroke prevention: anticoagulants for AF, statins, antihypertensives, antiplatelet agents, and lifestyle modification. In SELECT, semaglutide’s benefit was additive — most participants were already on these standard therapies.
Getting started
How to Access GLP-1 Medications #
Coverage update: Since the March 2024 FDA cardiovascular indication, more insurance plans cover Wegovy for patients with documented cardiovascular disease + obesity. Your cardiologist or neurologist can submit prior authorization citing the SELECT trial. If denied, telehealth platforms prescribe compounded semaglutide without insurance.
Telehealth Platforms That Prescribe GLP-1s #
FAQ
Frequently Asked Questions #
Does semaglutide reduce stroke risk?
Yes. In the SELECT trial (17,604 participants), semaglutide reduced major adverse cardiovascular events — including nonfatal stroke — by 20% compared to placebo. The earlier SUSTAIN 6 trial in people with type 2 diabetes found semaglutide reduced nonfatal stroke by 39%. These benefits occurred in addition to standard cardiovascular care.
How do GLP-1 medications help prevent strokes?
GLP-1s reduce stroke risk through multiple mechanisms: lowering blood pressure by 3-8 mmHg, reducing atherosclerotic inflammation (CRP drops ~40%), improving lipid profiles, reducing carotid intima-media thickness, and potentially stabilizing vulnerable arterial plaques. Weight loss itself also reduces stroke risk by improving metabolic health and reducing cardiac strain.
Is semaglutide FDA-approved for stroke prevention?
Semaglutide (Wegovy) is FDA-approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. This approval was based on the SELECT trial and was granted in March 2024. It is the first weight-loss medication ever approved for cardiovascular risk reduction.
Who benefits most from GLP-1 therapy for stroke prevention?
People with the highest risk profile benefit most: those with established cardiovascular disease, prior stroke or TIA, atrial fibrillation, carotid artery disease, uncontrolled hypertension, or multiple metabolic risk factors — especially when combined with obesity or overweight. The SELECT trial specifically enrolled people with existing heart disease.
Can I take a GLP-1 medication with my blood thinner or statin?
Yes. In the SELECT trial, most participants were already on statins, antihypertensives, and antiplatelet agents. Semaglutide’s 20% cardiovascular benefit was additive — it worked on top of standard therapy, not instead of it. GLP-1 medications do not interact with blood thinners, statins, or blood pressure medications. Never stop any cardiovascular medication without your doctor’s guidance.
How quickly does stroke protection begin on GLP-1 therapy?
In the SELECT trial, the cardiovascular event curves for semaglutide and placebo began separating within the first months of treatment — before maximum weight loss was achieved. This early divergence suggests that direct anti-inflammatory and vascular effects contribute to stroke protection beyond what weight loss alone would explain.
Keep reading
Related Guides #
Sources
Key References #
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. DOI
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. DOI
- Husain M, Bain SC, Jeppesen OK, et al. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6. Stroke. 2022;53(9):2749-2757. DOI
I'm not a doctor — just someone researching GLP-1 medications thoroughly. This article is for informational purposes only and should not replace medical advice. Always consult your neurologist or cardiologist before starting any new medication.
Questions? contact@glp1forwellness.com
Affiliate Disclosure: Some links earn a small commission at no extra cost to you. I only recommend platforms I've researched thoroughly.